Approval · Notice of Compliance 19043 · 2017
ACT OXYCODONE CR: Notice of Compliance 19043
Issued March 9, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19043
- Date
- March 9, 2017
- Company
- Actavis Pharma CompanyToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Revisions to the product monograph
- Canadian reference product
- OXYCONTIN (Purdue Pharma)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT OXYCODONE CR | Not yet assigned | — |
Medicinal ingredients
- OXYCODONE HYDROCHLORIDE 5 MG per TAB
- OXYCODONE HYDROCHLORIDE 10 MG per TAB
- OXYCODONE HYDROCHLORIDE 20 MG per TAB
- OXYCODONE HYDROCHLORIDE 40 MG per TAB
- OXYCODONE HYDROCHLORIDE 80 MG per TAB